Company / Financials
Aurinia Pharmaceuticals Inc. Financials
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$283.1M
FY2025 · +20.4% YoY
Net Income
$287.2M
FY2025 · +4893.1% YoY
Profit Margin
101.5%
FY2025 · net income / revenue
ROE
49.4%
FY2025 · return on equity
Total Assets
$751.6M
FY2025
Total Debt
-
FY2025
Equity
$581.3M
FY2025
ROA
38.2%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$283.1M+20.4% YoYNet Income HistoryProfit after all expenses and taxes$287.2M+4893.1% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$32.7M+15.6% YoYOperating Income HistoryProfit from core business operations before interest and taxes$104.9M+2338.4% YoYSG&A Expense HistorySelling, general, and administrative expenses$101.8M-40.8% YoYR&D Expense HistoryResearch and development spending$32.5M+56.4% YoYInterest Expense HistoryCost of borrowing and debt obligations$2.8MIncome Tax HistoryTotal income tax expense-$173.0M-10303.1% YoYEPS (Basic) HistoryBasic earnings per share-$0.54+28.9% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$0.54+28.9% YoY